Stock fact sheet · data as of
Inhibikase Therapeutics, Inc. (IKT): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is IKT undervalued?
Inhibikase Therapeutics, Inc. (IKT) closed at 1.83 on 16 Oct 2026, 30% above the GLS average fair value of 1.41. 1 of the 1 models that produced a number value the shares below the current price. A gap this wide usually means the market is paying for growth or a story the trailing numbers do not show yet; the models work from filed results, not forecasts, so they are conservative by design.
Only 1 of the nine models produced a value (DCF); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.
The nightly engine files IKT under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for IKT
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 1.41 | -23% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 1.23 | -33% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 4.83 | +164% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: IKT passes 2 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 0.9 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -27.9%, ROE -27.9%, ROA -26.6% - with debt at 0.00 times equity and negative free cash flow.
Inhibikase Therapeutics, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 8/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 2 / 9 | ROIC | -27.9% |
|---|---|---|---|
| GLS Moat | 0.9 / 10 | ROE | -27.9% |
| Debt / equity | 0.00 | ROA | -26.6% |
| Free-cash-flow yield | -16.9% | Payout ratio | 0% |
| Institutions | 8 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 16: No options
IKT has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (16 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 401k shares a day on a market cap of $255M, with a beta of 0.90; the Stability part of the Wheel Score gives that 10 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -30% margin of safety | |
| Health | 4 / 20 | Piotroski 2/9 | |
| Moat | 1 / 15 | moat 0.9/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 10 / 20 | 401k shares/day, $255M cap, beta 0.90 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 13 Nov 2026, 28 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Inhibikase Therapeutics, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals Inc. | 4.22 | - | - | 43Weak | $255M |
| NWBO Northwest Biotherapeutics, Inc. | 0.1500 | - | - | 30No options | $256M |
| VCRE Vicore Pharma Holding AB | 9.08 | 2.35 | -287% | 10No options | $256M |
| PALI Palisade Bio, Inc. | 1.48 | 2.39 | +38% | 39No options | $258M |
| BCYC Bicycle Therapeutics plc | 3.60 | - | - | 45Weak | $252M |
| LCTX Lineage Cell Therapeutics, Inc. | 0.9903 | - | - | 39Weak | $250M |
| ACIU AC Immune S.A. | 2.45 | - | - | 33Weak | $249M |
| CABA Cabaletta Bio, Inc. | 1.55 | 0.4921 | -215% | 18Weak | $263M |
| EYPT EyePoint Pharmaceuticals, Inc. | 3.14 | - | - | 37Weak | $263M |
| SGMT Sagimet Biosciences Inc. | 7.55 | 1.05 | -621% | 29Weak | $246M |
| ABEO Abeona Therapeutics Inc. | 4.65 | 0.9983 | -366% | 35Weak | $265M |
| GALT Galectin Therapeutics Inc. | 3.71 | - | - | 29Weak | $244M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about IKT
Is IKT undervalued right now?
No: at 1.83 the stock trades 30% above the GLS average fair value of 1.41 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of IKT and what does it mean?
IKT has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for IKT?
1.41 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Inhibikase Therapeutics, Inc. report earnings next?
The next earnings report is due on 13 Nov 2026, 28 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does IKT have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on IKT, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.